Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)
PRIMARY OBJECTIVE:
This is a pilot study to characterize the toxicity profile, to determine the maximum
tolerated dose of the combination of crenolanib and sorafenib, and to determine the
feasibility of administering these drugs in patients with relapsed or refractory hematologic
malignancies, including acute myeloid leukemia (AML), AML with prior myelodysplastic syndrome
(MDS), and myeloperoxidase (MPO)-positive mixed phenotype acute leukemia with FLT3-internal
tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations.
The study will include two phases:
- The dose-escalation phase will characterize the dose-limiting toxicities (DLTs) and
determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of
crenolanib when given in combination with sorafenib.
- The dose-expansion cohort will further assess the safety and explore the efficacy of
this combination.
Each course of therapy will be 28 days (±5 days), unless disease progression is seen while on
the combination of crenolanib with sorafenib. Patients may receive subsequent courses (up to
a total of 365 days) if there is no disease progression or unacceptable toxicity.
In Day 1 of Course 1, crenolanib is given once in the morning followed by characterization of
the pharmacokinetic profile over the following 24-hour period. Starting with day 2 of Course
1, crenolanib will be given 3 times per day through day 28. On Days 8 to 28 of Course 1,
sorafenib will be given once per day. Inter-patient dose escalation or de-escalation of
crenolanib will be performed based on tolerability and toxicity.
Response will be assessed on days 8 and at end of course. If disease progresses prior to day
8, then sorafenib can be given before day 8.
In subsequent courses (up to 365 days), crenolanib and sorafenib are given on days 1 through
28. The treating physician may increase or decrease the sorafenib dose and frequency of
administration per the trial's dosing table on the basis of effects and tolerability. If
necessary, the crenolanib dose can be decreased per protocol.
Maintenance therapy must start no sooner than 30 days and no later than 120 days after
hematopoietic stem cell therapy (HSCT). Single agent crenolanib will start at the last dose
tolerated prior to HSCT. Crenolanib maintenance can be given for up to 365 days and
additional therapy can be provided after discussion after discussion with the PI, in patients
who continue to benefit after 1 year.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |